Badmaarag Munkhjin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Badmaarag Munkhjin has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Anuujin Gantumur
Department of Microbiology and Infection Prevention Control, School of Biomedicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
1 shared publication - Baigalmaa Jantsansengee
National Center for Communicable Diseases, Ulaanbaatar, Mongolia
1 shared publication - Battogtokh Chimeddorj
Institute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
1 shared publication - Battur Lkhagvaa
The National Center for Public Health, Ulaanbaatar, Mongolia
1 shared publication - Bilegtsaikhan Tsolmon
Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
1 shared publication Bumdelger Batmunkh
National Center for Communicable Diseases Ulaanbaatar Mongolia
1 shared publication
Latest Publications
- 28 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (10)
A Novel Quantitative ELISA Demonstrates Lack of Correlation Between Serum HDV ‐ RNA and Anti‐ HDV Antibody Levels in Chronic HDV Infection
Infection with the hepatitis delta virus (HDV) causes the most aggressive type of viral hepatitis and frequently leads to liver cirrhosis and hepatocellular carcinoma. Immunological aspects associated with HDV infection are poorly studied, and quantitative identification of anti‐HDV antibodies may be important for understanding the disease. A quantitative, chemiluminescence‐based ELISA was developed and validated using 399 serum samples (199 HDV‐Ab positive, 200 healthy controls). Serum levels of HDV‐RNA, HBV‐DNA and hepatic enzymes (ALT, AST) were measured. Statistical analyses included ROC analysis, distribution analysis, Student's t ‐test and correlation analysis. ELISA demonstrated linear quantification of anti‐HDV antibodies with high specificity (Sp = 100%) and sensitivity (Se = 100%), detecting down to 0.5 ng/mL in pure standards. The mean anti‐HDV antibody levels were 67,622 ng/mL overall, 70,883 ng/mL in males and 64,043 ng/mL in females. Antibody levels followed a normal distribution, despite population heterogeneity. Student's t ‐test revealed significant gender differences in antibody levels and ALT ( p = 0.0128 and p = 0.0006), whereas HDV‐RNA, HBV‐DNA and AST did not differ significantly. Comparisons of the high versus low HDV‐RNA subgroups showed no significant differences in antibody levels. Correlation analysis indicated no significant associations between anti‐HDV antibody levels and HDV‐RNA, hepatic enzyme levels. This study presents a robust quantitative ELISA for detecting anti‐HDV antibodies. The humoral immune response, as reflected by antibody levels, is independent of the viral load and liver injury markers. Gender‐related differences in antibody and ALT levels were observed. These findings provide a foundation for precise evaluation of HDV‐specific immunity in chronic infections.
- 28 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (10)
A Novel Quantitative ELISA Demonstrates Lack of Correlation Between Serum HDV ‐ RNA and Anti‐ HDV Antibody Levels in Chronic HDV Infection
Infection with the hepatitis delta virus (HDV) causes the most aggressive type of viral hepatitis and frequently leads to liver cirrhosis and hepatocellular carcinoma. Immunological aspects associated with HDV infection are poorly studied, and quantitative identification of anti‐HDV antibodies may be important for understanding the disease. A quantitative, chemiluminescence‐based ELISA was developed and validated using 399 serum samples (199 HDV‐Ab positive, 200 healthy controls). Serum levels of HDV‐RNA, HBV‐DNA and hepatic enzymes (ALT, AST) were measured. Statistical analyses included ROC analysis, distribution analysis, Student's t ‐test and correlation analysis. ELISA demonstrated linear quantification of anti‐HDV antibodies with high specificity (Sp = 100%) and sensitivity (Se = 100%), detecting down to 0.5 ng/mL in pure standards. The mean anti‐HDV antibody levels were 67,622 ng/mL overall, 70,883 ng/mL in males and 64,043 ng/mL in females. Antibody levels followed a normal distribution, despite population heterogeneity. Student's t ‐test revealed significant gender differences in antibody levels and ALT ( p = 0.0128 and p = 0.0006), whereas HDV‐RNA, HBV‐DNA and AST did not differ significantly. Comparisons of the high versus low HDV‐RNA subgroups showed no significant differences in antibody levels. Correlation analysis indicated no significant associations between anti‐HDV antibody levels and HDV‐RNA, hepatic enzyme levels. This study presents a robust quantitative ELISA for detecting anti‐HDV antibodies. The humoral immune response, as reflected by antibody levels, is independent of the viral load and liver injury markers. Gender‐related differences in antibody and ALT levels were observed. These findings provide a foundation for precise evaluation of HDV‐specific immunity in chronic infections.
- Open Access
- 13 December 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (12) , e1095
Molecular epidemiology of SARS‐CoV‐2 in Mongolia, first experience with nanopore sequencing in lower‐ and middle‐income countries setting
Background: Coronavirus disease (COVID‐19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two‐stepped, nationally representative molecular epidemiologic study of SARS‐CoV‐2 in Mongolia for 2020 and 2021.Methods: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant‐specific real‐time reverse transcription polymerase chain reaction (RT‐PCR) test to detect SARS‐CoV‐2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at −70°C deep freezer, and tests were performed on samples with cycle threshold <30.Results: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia.Conclusions: SARS‐CoV‐2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS‐CoV‐2 from Mongolia, where sequencing data is sparse.
- 13 December 2023
- Published by Wiley in Immunity, Inflammation and Disease
- Vol. 11 (12) , e1095
Open AccessMolecular epidemiology of SARS‐CoV‐2 in Mongolia, first experience with nanopore sequencing in lower‐ and middle‐income countries setting
Background: Coronavirus disease (COVID‐19) has had a significant impact globally, and extensive genomic research has been conducted on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) lineage patterns and its variants. Mongolia's effective response resulted in low prevalence until vaccinations became available. However, due to the lack of systematically collected data and absence of whole genome sequencing capabilities, we conducted a two‐stepped, nationally representative molecular epidemiologic study of SARS‐CoV‐2 in Mongolia for 2020 and 2021.Methods: We used retrospective analysis of stored biological samples from November 2020 to October 2021 and a variant‐specific real‐time reverse transcription polymerase chain reaction (RT‐PCR) test to detect SARS‐CoV‐2 variants, followed by whole genome sequencing by Nanopore technology. Samples were retrieved from different sites and stored at −70°C deep freezer, and tests were performed on samples with cycle threshold <30.Results: Out of 4879 nucleic acid tests, 799 whole genome sequencing had been carried out. Among the stored samples of earlier local transmission, we found the 20B (B.1.1.46) variant predominated in the earlier local transmission period. A slower introduction and circulation of alpha and delta variants were observed compared to global dynamics in 2020 and 2021. Beta or Gamma variants were not detected between November 2020 and September 2021 in Mongolia.Conclusions: SARS‐CoV‐2 variants of concerns including alpha and delta were delayed in circulation potentially due to public health stringencies in Mongolia. We are sharing our initial experience with whole genome sequencing of SARS‐CoV‐2 from Mongolia, where sequencing data is sparse.